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ABSTRACT 
Nerve growth factor (NGF) binds to its receptor, TrkA, at the tips of nerve cell axons 
to inhibit apoptosis, causing survival and differentiation. Some factors within this 
process are largely unknown, such as the role of the p75 receptor and the molecular 
mechanisms that occur within the cell. NGF binding causes dimerization of TrkA, 
which activates the intracellular kinase domain. Autophosphorylation on tyrosine 
residues stimulates binding to the receptor of several intracellular proteins that mediate 
the NGF response. This receptor complex has been demonstrated to be retrogradely 
transported to the cell body. Retrograde transport is hypothesized to occur in small 
vesicles that have been isolated in our lab using a cell fractionation protocol using in 
vitro reactions with an ATP regenerating system. Discovering the initial molecular 
interactions that occur upon NGF binding could further our knowledge of NGF's 
inhibition of apoptosis, providing us with a possible tool for treatment of diseases that 
occur when the regulation of apoptosis no longer exists. 
Novel proteins that were not previously identified were associated with TrkA in small 
vesicles after NGF activation. To isolate these proteins for further characterization, 
TrkA's intracellular domain (TrkAID) was expressed in E. Coli . This protein was 
found to be constitutively tyrosine-phosphorylated and therefore presumably active. In 
E.Coli, TrkAID protein was localized to the soluble fraction but smaller amounts were 
detected in the insoluble fraction . TrkAID was partially purified from the soluble 
fraction using a combination of salt disruption and denaturing techniques. The 
un:rnrifierl Trk A ID w::i<: imrn1JT1n!_lrf'.ririt::itl"rl frnm thl" h::irtpri ::d <:nh1hlP frnrtinn with ;:m 
antibody to the C-terminus of TrkA, and some results suggest that immunoprecipitated 
TrkAID was able to stimulate ERK activation in untreated PC12 cells, but 
unfortunately this was not reproducible. 
If the protein could be purified with a combination of techniques, then it would provide 
a useful tool for studying the initial events in NGF stimulation, that is, the recruitment 
of several intracellular proteins to the tyrosine-phosphorylated intracellular domain of 
TrkA. 
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CHAPTER 1 INTRODUCTION 
1.1: Overview of apoptosis 
Apoptosis (regulated cell death) is an important mechanism in the development of 
neuronal cells. A cascade of intracellular reactions results in changes in cell structure, 
DNA and ultimately neuronal cell death (apoptosis). Cellular death is determined by 
the binding of the neurotrophin nerve growth factor (NGF) to its extracellular receptor 
resulting in one of two responses, proliferation or a mitogenic response in vivo. Which 
response occurs depends on the intracellular proteins that are activated. 
NGF was first recognised as a neurotrophin by Levi-Montalcini and Angeletti (1963) 
and was shown to be important for the survival and differentiation of neurons in the 
peripheral and central nervous system (Barde, 1989). NGF also promoted the 
differentiation of the rat pheochromocytoma tumour cell line, PC12, into cells 
resembling sympathetic neurons (Greene and Tischler, 1976). For this reason the 
PC12 cell line provides a useful model to study NGF action. 
The intracellular processes that occur during the inhibition of apoptosis can be split 
into three separate stages; the binding of NGF to its receptor on the neurite tip, 
transport of the NGF activated receptor from the neurite tip to the cell body, and the 
activation of the intracellular proteins that regulate NGF-induced inhibition of 
apoptosis. 
Apoptosis must be tightly regulated to ensure brain function is not compromised. It 
has been theorised that if apoptosis is over active then the result is large amounts of 
cellular death resulting in the formation of certain types of dementia such as 
Alzheimer's disease. If apoptosis is inhibited then over-proliferation of cells is seen as 
in some forms of cancer. Understanding the mechanism of apoptosis may eventually 
lead to the ability to manipulate apoptosis as required. 
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1.2: Aim 
The aim of the project was to characterize the initial events of NGF-induced survival 
by studying the intracellular proteins that bind the NGF-activated receptor and to 
identify any novel intracellular proteins that are activated by NGF. The following 
results show the existence of at least one 90 KDa intracellular protein that may not 
have been previously characterized or identified (Dr. M. L. Grimes, unpublished 
results). One other aim was to express and purify the intracellular domain of the NGF 
receptor, TrkA. These results could be used in conjunction with results from other 
members of the research group to characterize the whole process of apoptosis and to 
identify those steps at which regulation is crucial. 
1.3: Identification of the NGF receptor 
The first step in characterizing the inhibition of apoptosis by NGF was to identify the 
NGF receptor. Two types of NGF receptor were shown to exist in NGF-responsive 
primary neurons by Sutter et al. (1979). These receptors were also shown to exist on 
the membranes of NGF-responsive cell lines such as PC12 cells (Greene and Tischler, 
1976, Bernd and Greene, 1984, Meakin and Shooter, 1991). One of the receptors, the 
low affinity NGF receptor (LNGFR), with a Ki value of 10-9 M, does not bind NGF 
very tightly and NGF dissociates from the receptor quite rapidly. The other receptor, 
the high affinity NGF receptor (HNGFR) has a Ki value of 10-l l M so NGF dissociates 
from this receptor in a slow manner. 
In the paper by Meakin and Shooter (1991) binding of 1251-NGF to the membranes of 
PC12 cells followed by chemical crosslinking showed the existence of these two NGF 
receptors on the cell membrane. The LNGFR resolved at 77 K.Da on a SDS gel, and 
the HNGFR resolved at 135 KDa on the same SDS gel. They failed to 
immunoprecipitate any of the receptors with antibodies against src, ras or raj-I. This 
1-2 
suggested that these common intracellular signaling proteins were not in any kind of 
complex with either of the receptors. They also found phosphotyrosine residues on the 
HNGFR but not the LNGFR. 
These results taken together showed that the NGF response is mediated through either 
one or both of the receptors. The identification of the phosphotyrosine residues on the 
HNGFR suggested that the HNGFR transduced the NGF signal through a kinase 
cascade discussed below. The next step was to characterize these receptors . 
1.3.1 : Identification of the HNGFR as TrkA 
Kaplan et al. (1991 a) identified the HNGFR as pl 40prototrk , a protein tyrosine kinase 
also called TrkA. TrkA is a member of the receptor tyrosine kinases that have a large 
extracellular ligand binding domain, a single transmembrane domain and an 
intracellular catalytic domain. Expression of trk in vivo is limited to the neural 
crest-derived portions of the nervous system (Martin-Zanca et al., 1986). 
Kaplan ' s results showed the activation of TrkA (tyrosine phosphorylation) in response 
to picomolar amounts of NGF. To test if NGF directly binding TrkA achieved 
activation of TrkA, 1251-NGF was chemically crosslinked to cells and either NGF or 
TrkA was immunoprecipitated. In both of these immunoprecipitations, the presence of 
a 160 KDa protein was found. This co-precipitation was blocked by the addition of a 
peptide derived from TrkA. They concluded that NGF activates TrkA by directly 
binding it. The 160 KDa protein was believed lo be TrkA an.ct NGF. Ho'.vever Kapl<!.11 
( 1991 a) did report that "p 140prototrk alone does not have the binding characteristics of a 
high affinity receptor" suggesting a complex of the two receptors was required for the 
formation of a high affinity receptor for NGF. He also noted that NGF could activate 
TrkA in the absence of LNGFR, so TrkA might act independently of the second 
receptor. This begs the question, what is the role of the LNGFR? 
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Once the HNGFR was identified, the next step was to identify its effects in vivo. This 
was done in a study by Smeyne et al. (1994). They removed the trk proto-oncogene in 
mice embryonic stem cells. The resulting abnormalities showed that TrkA was the 
primary mediator of NGF action in the development of both the peripheral and central 
nervous system. 
Hempstead et al. ( 1992) also demonstrated the importance of TrkA in mediating the 
NGF response. NGF-treated PC12 cells developed neurite extensions after two days 
following continual NGF exposure. When trk was overexpressed in PC12 cells 
NGF-mediated, neurite extension occurred in a matter of hours rather than days. This 
demonstrated that TrkA was important for NGF mediated neurite extension in PC12 
cells and that NGF treatment of these cells resulted in an increased level of tyrosine 
phosphorylation of TrkA. This suggested a mechanism for the propagation of the NGF 
signal through the use of a signaling cascade system mediated by TrkA tyrosine kinase 
activity, which will be discussed in greater detail in section 1.4. 
All these results had suggested a model for TrkA function. The function of LNGFR 
was less clear. It was also unclear whether TrkA had any effect on the activity of 
LNGFR. To look at these points the activity of the LNG FR needed to be determined. 
1.3.2: The role of p75LNGFR in NGF signaling. 
The role of the LNGFR receptor (p75) had been debated for a number of years. It had 
been theorized that if the neurotrophins were present m picomoiar concentrnt.iurn,, ther, 
the formation of high affinity binding sites would act to discriminate similar ligands. 
Since all the neurotrophins bound p75 it was possible that p75 assisted in the binding 
of the correct neurotrophin to the appropriate Trk receptor (Rodriguez-Tebar et al., 
1992). The important question was whether p75 acted as a presenter of NGF or 
whether p75 formed a complex with TrkA. Another possibility was that p75 acted as a 
separate receptor with either a separate signaling cascade system or some influence on 
the TrkA signaling cascade system. 
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P75 forming a complex with TrkA to form the high affinity binding site 
There was conflicting evidence supporting the theory that p75 was m complex 
formation with TrkA. Low concentrations of NGF binding to p75 enhanced binding of 
NGF to TrkA and its autophosphorylation (Barker and Shooter, 1994; Verdi et al., 
1994) as well as activation of the immediate early gene c-fos (Barker and 
Shooter, 1994). Physical evidence for the formation of a complex between p75 and 
TrkA is scarce (Jing et al., 1992). 
One important event to note was that stimulation of PC12 cells with NGF resulted in 
the induction of p75 (Higgins et al., 1989) and TrkA mRNA levels (Meakin et al., 
1992). When p75 and TrkA were co-expressed in the proper ratio, substantial numbers 
of high affinity binding sites were observed. Deletion mutants in p75 abolished high 
affinity binding sites (Hempstead et al. , 1990). This suggested that an intact p75 was 
required for the formation of the high affinity binding sites and that their formation 
was dependent on particular ratios of p75 to TrkA. The level of p75 mRNA was five 
to ten times greater than the level of TrkA mRNA in PC12 cells (Chao and Hempstead, 
1994). These rnRNA levels have been confirmed using 1251 labelled NGF to count the 
number of p75 and TrkA receptors (Meakin and Shooter, 1994). Studies by Ip et al., 
(1993) and Ibanez et al., (1992) excluded a role of p75 from neurotrophin action, but 
they did not analyse NGF binding under high affinity conditions, nor did they measure 
the rnRNA levels of the two receptors. 
The above results are evidence for the role of p75 as a partner for the high 
affinity-binding site for NGF. The high affinity-binding site could be assumed to be a 
multimeric complex of p75-TrkA proteins. 
Does Trk.Afunction dependently or independently of the LNG FR? 
Below is depicted a diagram showing two possible models describing the co-operation 
of TrkA and p7_5. 
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In the presenter model, p75 binds NGF with low affinity. P75 is co-localized on the plasma 
membrane with TrkA, therefore NGF is able to bind TrkA with higher affinity. Thus p75 acts as a 
presenter. 
In the complex model, TrkA and p75 are in a complex to form the high affinity receptor for NGF. 
Once NGF is hound to the comnlex it stimulates a kinase cascade through TrkA 
The function of the two receptors with different affinity for NGF was a matter of 
debate. Was the NGF binding site a combination ofTrkA and different factors, such as 
the other NGF receptor? Was TrkA involved in both the low affinity and high affinity 
NGF binding sites or just one? How did TrkA function when NGF was bound? 
Evidence for the existence of the HNGFR being a complex between p75 and TrkA was 
put forward by Hempstead et al. (1992). Overexpression of trk resulted in an increase 
in both the high affinity and low affinity binding sites suggesting TrkA seemed to be 
involved in the formation of both these sites. 
Ross et al. (1996) provided evidence for the existence of a complex of the two 
receptors. Using antibodies to p75LNGFR and TrkA, followed by fluorescent secondary 
antibodies, they showed that p75LNGFR co-patched with Trk.A in both the absence and 
presence of NGF. p75LNGFR was not found to co-patch with other receptor tyrosine 
kinases, so the association between the two receptors was quite specific. Expression of 
chimeric receptors identified the extracellular domain of TrkA as sufficient for this 
co-patching. A point mutation of the TrkA kinase domain did not affect the 
co-patching but a deletion of the intracellular domain reduced it. This paper indicated 
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that the p75LNGFR and TrkA might form a complex to mediate the NGF response. 
Complex formation required the TrkA extracellular domain but the intracellular 
domain may also play a role. 
This paper does not prove the existence of heterodimers of the two receptors; it only 
provides evidence for the co-localization of them. Therefore, this result could also be 
evidence for the presenting model. If the two receptors are in close proximity to each 
other then it is plausible that the p75LNGFR acts as a recruiter of NGF for TrkA. 
One study that disproved the complex theory and provided an answer to TrkA function 
was performed by Jing et al. (1992). Using cell lines expressing TrkA, p75LNGFR or 
both together they found that NGF induced the tyrosine phosphorylation of TrkA in the 
presence and absence of p75LNGFR _ Crosslinking studies revealed the existence of 
TrkA and p75LNGFR homodimers but no heterodimers were detected. Sutter et al. 
( 1979) only mediated the NGF biological response through TrkA, which formed 
homodimers and exhibited a dissociation constant equivalent to that of the HNGFR 
reported previously. Co-expression of wild type and kinase deficient TrkA receptors in 
COS cells revealed that TrkA was capable of undergoing autophosphorylation on 
tyrosine residues in response to NGF. Furthermore, co-expression of the kinase 
deficient mutant and wild type TrkA inhibited the NGF response. These results 
suggested that the HNGFR consisted of TrkA alone. The NGF response appeared to 
be dependent on the formation of TrkA homodimers and this dimer formation was 
critical for the NGF-induced tyrosine phosphorylation of TrkA through its own kinase 
domain. The authors suggested that the p75LNGFR functions as a "presenter" of NGF to 
TrkA by localizing NGF to regions of the membrane where TrkA receptors are 
rl11<::tPrPrl with n7-iLNGFR 
- · - --- -- - - - . - ---- r . -
Evidence for a functional dissociation between the two was also shown by Ibanez et al. 
(1992). They mutated critical lysine residues on NGF (K32, K34 and K95) required 
for NGF binding to p75LNGFR and found that abolishing the binding of NGF to 
p75LNGFR led to no inhibition of NGF biological activity. 
Further evidence for the functional dissociation of the two receptors was provided by 
other groups (Cordon-Cardo et al., 1991, Rovelli et al., 1993). These studies used a 
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combination of experimental techniques. Cordon-Cardo et al. transfected NIH 3T3 
cells with Trk.A and found that a mitogenic response was induced upon treatment with 
NGF. This rnitogenic response was abolished in cells not expressing TrkA. Revelli et 
al. transfected PC12 cells with chimeric receptors consisting of the extracellular 
domain of tumour necrosis factor (TNF) receptor and the transmembrane domain and 
cytoplasmic domain of either Trk.A or p75LNGFR_ TNF treatment of these cells resulted 
in neurite extension in those cells transfected with the TNF-Trk.A chimera. No 
response to TNF was observed in those cells transfected with the TNF-p75LNGFR 
chimera. This latter result supported the theory that Trk.A is sufficient in mediating the 
NGF response. 
All the above results have led to the following model of TrkA activation in NGF 
signalling. Trk.A appears to be the primary receptor for NGF and the main mediator of 
the NGF response. Binding of NGF to Trk.A results in the formation of TrkA 
homodimers. This results in the activation of the receptors kinase domain leading to 
cross-phosphorylation of tyrosine residues on the intracellular domain of the receptor 
providing a start for the signal to be transduced within the cell via a signaling cascade 
system. The protein pathways involved in this cascade will be discussed later in 
section 1.4. It remains unclear as to whether TrkA forms a complex with p75 or 
whether it acts independently to form the HNGFR. If it acts independently the 
question must be asked; what is the function of p75? 
P75 stimulates a signaling cascade 
Another possible role for p75 is that it initiates a separate signaling cascade system or 
modifies the TrkA signaling cascade. The suggestion of a signaling cascade function 
for p75 is due to its structural resemblance to the TNF receptor family. A number of 
protein kinases have been found to be associated with p75 (Ohmichi et al., 1991) 
including the rnitogen activated protein kinases (MAPK or extracellular regulated 
kinase, ERK) (Volente et al., 1993b). The manner in which p75 contributes to NGF 
signaling could either be through a direct interaction of NGF to p75 or indirectly via 
TrkA activation. 
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Canossa et al., ( 1996) showed the association of a protein kinase approximately 
120 KDa in size with the p75 receptor that was activated upon NGF treatment in PC12 
cells. It was undetermined if the protein kinase was constitutively associated with the 
p75 receptor or whether the protein kinase was recruited upon NGF stimulation. This 
protein kinase was responsible for most of the kinase activity found associated with the 
receptor. In addition to this protein kinase they observed the association of two other 
protein kinases of approximately 44 KDa and 56 KDa. The authors suspected that the 
44 KDa kinase may be ERK but this remains unclear. The identity of the 56 K.Da 
kinase was also unknown. The rapid activation of the 120 KDa-protein kinase 
suggested that it lies upstream of ERK in the NGF signaling cascade. Since the p75 
receptor was suggested to have some role in ceramide signaling (Dobrowsky et al. , 
1994), Canossa et al. tested the protein kinase for activation with a ceramide 
homologue but found that the protein kinase was not a ceramide-activated protein 
kinase. The activation of this protein kinase was rapid when the NGF concentration 
was at low levels and was dependent on both TrkA autophosphorylation and NGF 
binding to p75 . In the absence of NGF, or when the ratio of TrkA to p75 was 
decreased, only slow activation of this kinase was observed. The requirement for TrkA 
and Trk.A activation in the activation of this protein kinase by NGF suggested a 
functional coupling of the two receptors, if not a physical coupling. 
A review by Bredesen and Rabizadeh (1997) suggested TrkA-independent and 
TrkA-dependent effects for p75 . Without ligand binding a pro-apoptotic signal is 
generated, once NGF binds TrkA the signal is blocked and other, anti-apoptotic 
signaling events take over. This pro-apoptotic signal may be stimulated by the p75 
receptor and is believed to be TrkA independent. NGF binding to p75 resulted in 
ceram.ide formation (Dobrowsky et al., 1994) and in so111e systems, ceramide has been 
shown to inhibit apoptosis (Ito and Horigome, 1995). This effect on p75 could require 
the interaction of the p75 transmembrane domain or extracellular domain with another 
molecule (Bredesen and Rabizadeh, 1997). 
The Trk.A-dependent effects of p75 include mutual signaling with TrkA and the role of 
p75 in the formation of high affinity binding sites with TrkA. Hempstead et al., 
(1990,1991) demonstrated that co-expression of TrkA with p75 resulted in an increase 
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in the number of high affinity binding sites than TrkA alone. It was possible that the 
anti-apoptotic effect of low levels of NGF could require the presence of p75 without 
NGF stimulating a signal from p75 . Also, as shown in the paper by Canossa et al., 
(1996), the ratio of p75 to TrkA was critical to the cellular response indicating mutual 
effects on signalling by TrkA and p75 . Finally, it was possible that p75 and TrkA 
exhibit mutual repression. The expression of one of the signalling cascades inhibited 
the anti-apoptotic effect of the other signaling pathway. A maximal signal was only 
generated by co-stimulation, which relieved the mutual repression (Bredesen and 
Rabizadeh, 1997). It could also be possible that p75 inhibits the anti-apoptotic effect 
of TrkA by binding directly to it. This would decrease the chance of TrkA 
dimerization thus decreasing the amount of anti-apoptotic signaling that would 
otherwise occur. 
The p75 receptor may cause apoptosis when expressed in the absence of TrkA. It may 
also enhance binding and presentation to TrkA, promoting survival. To summarize the 
evidence presented here there is a suggestion of a role for p75 as a member of the high 
affinity-binding site (see Figure 2). TrkA can dimerise and initiate an anti-apoptotic 
signal (discussed above). Either p75 can signal independently of TrkA in a 
pro-apoptotic manner, or it can associate with TrkA to decrease the anti-apoptotic 
signal thus initiating a pro-apoptotic response. Upon NGF binding the pro-apoptotic 
signal is inhibited and the TrkA anti-apoptotic signal is stimulated. 
The model shown in Figure 2 is a crude representation of what occurs within the cell, 
simplified for the convenience of explanation. With future study into the role of p75 , a 
clearer model will be presented. 
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P75 signaling in equilibrium P75 binds TrkA and inhibits TrkA signaling. 
Figure 2 
Role of p75 in signaling 
P75 may be responsible for stimulating a signaling cascade that results in apoptosis. This cascade 
may be inhibited once TrkA, and thus survival, is stimulated by NGF binding. Therefore, the 
signaling cascades are in an equilibrium with each other. 
P75 may bind TrkA thus inhibiting the cascade that stimulates survival, resulting in apoptosis. 
Once NGF binds TrkA the survival signal is stimulated inhibiting apoptosis. 
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1.4: The TrkA Signaling Cascade System 
Once the receptor for NGF had been discovered, the next issue to be determined was 
how the NGF signal was transduced from TrkA. The answer to this first came from 
the fact that TrkA underwent autophosphorylation on tyrosine residues in response to 
NGF (Kaplan et al., 1991a). Hempstead et al., (1992) showed the phosphorylation of 
several intracellular proteins in PC12 cells overexpressing TrkA, including the 
appearance of several tyrosine phosphorylated intracellular proteins in response to 
NGF (Maher et al., 1988). 
1.4.1: TrkA recruits intracellular proteins to its intracellular domain 
The paper by Hempstead et al. ( 1992) identified two proteins that were tyrosine 
phosphorylated upon NGF stimulation, PLC-yl and ERK-1. Vetter et al. (1991) linked 
PLC-yl and TrkA activation by NGF. Immunoprecipitation of PLC-yl from 
NGF-treated cells also co-precipitated a 140 KDa protein with kinase activity that they 
identified as TrkA by immunodepletion with antibodies against TrkA. These results 
taken together provided strong evidence for the propagation of the NGF signal in cells 
through TrkA tyrosine kinase activity. 
Other intracellular proteins were activated in response to NGF. Phosphatidylinositol-3 
(Soltoff et al., 1992). The activation of ERK-1 was also shown to occur after NGF 
treatment (Loeb et al., 1992, Hempstead et al. , 1992). Rozakis-Adcock et al. (1992) 
showed that src homology containing proteins (SHC) are recruited to Trk.A 
intracellular domain in response to NGF. An important step was identifying those 
proteins that associated with Trk.A either directly or indirectly, and identifying the sites 
at which these proteins bind. 
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Intracellular proteins interact with TrkA on specific phosphotyrosine residues 
Obermeier et al., (1993a) showed NGF activation of TrkA caused the association and 
activation of PLC-yl , ras GTPase activating protein (ras-GAP), and the non-catalytic 
subunit of PI-3K (p85). They constructed chimeric receptors consisting of the EGF 
extracellular domain and the TrkA transmembrane and intracellular domains. This 
chimeric receptor showed the association with TrkA and tyrosine phosphorylation of 
PLC-yl , rasGAP and PI-3K. A deletion of the cytoplasmic tail , involving the removal 
of the terminal 15 amino acids including Y-785 inhibited activation and association of 
the intracellular proteins with TrkA. A single point mutation (Y785F) resulted in the 
loss of PLC-yl activation and association with TrkA, but only a small reduction in 
activation of PI-3K and rasGAP was seen. These results indicated that the cytoplasmic 
tail of TrkA is critical for protein recruitment and activation. It also showed that 
PLC-yl binds TrkA at Y785 . 
In a subsequent study (Obermeier et al., l 993b) the binding and activation of two other 
signaling proteins, PI-3K and SHC, was investigated. Rozakis-Adcock et al. (1 992) 
had previously shown that SHC links TrkA to the ras pathway through other 
intracellular proteins. Obermeier et al. ( 1993b) expressed a number of peptides that 
contained each of the tyrosine residues found on the intracellular domain of TrkA. 
They discovered that the peptide containing Y-490 inhibited the TrkA-dependent 
activation of SHC and inhibited the association of SHC with TrkA. The peptide 
containing Y-751 blocked the TrkA dependent activation of p85 as well as the 
association of p85 with TrkA. This paper identified the binding sites of p85 (Y-751 ) 
and SHC (Y-490). 
SHC had been shown to contain a src homology domain by Pelicci et al. ( 1992). Other 
intracellular signaling proteins that had been shown to associate with NGF-activated 
TrkA also contain an SH2 domain. It is through these SH2 domains that proteins are 
able to specifically bind NGF-activated TrkA on the receptors phosphotyrosine 
residues (reviewed in Cantley et al. , 1991). 
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Different signaling cascades are activated by TrkA to mediate the NGF response 
Once the bjnding sites of these intracellular proteins had been identified, the next step 
was to determine the roles of these proteins. Stephens et al . (1994) did this by 
mutating the binding sites of PLC-yl (Y-785) and SHC (Y-490) on TrkA. They 
expressed these mutant receptors in cells that do not express any endogenous TrkA. 
Mutations in either of these binding sites had no effect on NGF-mediated neurite 
extension and ERK-1 activation. Mutations in both binding sites resulted in the 
inhibition of NGF-mediated neurite extension and ERK-1 activation. Although neurite 
extension and ERK-1 activation did not occur upon NGF treatment of the receptors 
containing the double mutation, phosphorylation of an intracellular protein called 
sue I-associated neurotrophic factor target (SNT) still occurred. These results 
provided evidence for the existence of two independent signaling pathways. There is 
some redundancy in NGF signaling; if one pathway is inhibited then the other pathway 
can still mediate NGF-induced neurite extension. The protein SNT seems to be 
involved in a separate, ERK-1 independent, signaling pathway. 
The roles of the different domains of TrkA in NGF signaling were determined in a 
study by Peng et al. (1995). They deleted a conserved region of the juxtamembrane 
domain. NGF treatment of cells expressing these mutant receptors did not promote 
neurite extension but did enhance survival. Cells expressing the mutant receptors were 
still receptive to NGF-stimulated survival and were capable of autophosphorylation as 
well as activation of the proteins involved in the ms-dependent pathway. SNT was 
not activated upon treatment with NGF. These results indicated that ras-dependent 
pathways mediate NGF-stimulated survival. The results also suggested that 
ras-independent pathways mediate neurite extension induced by NGF. One of the 
ms-independent pathways involves the activation of the protein SNT. This result also 
shows that TrkA can stimulate signaling pathways through methods other than kinase 
activity. This does not exclude the theory that both ms-dependent and independent 
pathways mediate neurite extension. There is evidence for the requirement of ms for 
NGF-stimulated neurite extension (Thomas et al., 1992, Hagag et al., 1986). 
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The binding of NGF to its receptor stimulates signaling cascades within the cell that 
mediate the response. These signaling pathways occur in the cell body with the protein 
targets being located in the nucleus. For these targets to be activated the signal needs 
to be transported from the plasma membrane through signaling vesicles (Grimes et al. 
1996, 1997). These signaling vesicles are produced by endocytosis. 
1.5: Endocytosis 
The method of endocytosis discussed in this section is clathrin-mediated, also known 
as receptor-mediated endocytosis. Clathrin-independent endocytosis can also occur 
but will not be dealt with in this discussion. Endocytosis involves budding of a region 
of the plasma membrane containing NGF-bound TrkA to form a clathrin-coated 
vesicle. This vesicle containing activated TrkA as well as several intracellular proteins 
fuses and buds off from various intracellular organelles to arrive at its destination 
within the cell body. These organelles include early and late endosomes, lysosomes, 
endoplasmic reticulum and golgi. Endocytosis occurs for receptor recycling, protein 
degradation as well as transport of the NGF signal. 
Coated vesicles are composed of clathrin triskelia, clathrin light and heavy chains 
arranged into a three-armed (triskelion) molecule. Triskelion molecules arrange 
themselves into "cages" to coat the vesicle. Assembly of the clathrin coat is dependent 
on the recruitment of AP2 proteins. AP2 recruitment to the section of plasma 
membrane that is to be budded off is believed to occur through its high affinity for the 
cytoplasmic domains of various proteins that associate with the plasma membrane. 
This AP2 lattice then provides a site where the clathrin triskelia can form a coat 
(Robinson, 1994; De Camilli and Takei , 1996). Formation of clathrin coats is ATP 
and GTP-dependent. Subsequent bending of the coated patch of membrane to form a 
dome shaped vesicle then a vesicle with a long narrow neck can occur in ATP-depleted 
preparations (Schmid, 1993). 
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The formation of a free vesicle from this budded state requires the activity of a protein 
called dynamin. Dynamin forms a ring at the neck of invaginated clathrin pits and is 
able to stimulate GTP hydrolysis. Hydrolysis of GTP could twist the ring 
conformation of dynamin to sever the neck (reviewed in DeCamilli and Takei, 1996). 
Dynamin contains a pleckstrin homology (PH) domain and proline rich C-terminus. 
This proline rich sequence can bind SH3 domains of various intracellular proteins 
(Gout et al. , 1993). The neuronal protein amphiphysin is co-localized with dynamin 
nerve terminals and interacts with AP2 (Wang et al., 1995; David et al., 1996). 
Therefore amphiphysin may play a role in recruiting dynarnin at clathrin coats. 
Dynamin could also interact directly with AP2 or proteins that contain SH3 domain 
such as Grb2, PI3K or PLCy-1. 
After fission, the vesicles need to shed their clathrin coats. This occurs via an 
ATP-dependent reaction that involves the heat shock protein Hsc70 (uncoating 
ATPase) and Auxilin (Ungewickell et al., 1995). Auxilin binds to the clathrin coat 
recruiting Hsc70 to it. This disrupts the clathrin lattice and releases the coat 
(Ungewickell et al., 1995). 
The requirement for ATP m vesicle budding and fusion can be utilized for our 
purposes (see Figure 3). In vivo, vesicles fuse with the target compartment in an 
ATP-dependent manner. In cells that have been permeabilised, the vesicles will leak 
out of the cell instead of fusing with their target compartment. The addition of an in 
vitro reaction with an ATP regenerating system (ATP, creatine kinase and creatine 
phosphate) will increase the number of vesicles formed and these vesicles will be 
unable to fuse with intracellular organelles. This would provide an opportunity for 
election of a larr;e pn1:11l::1tinn nf ~igD~ling vesicles in perme<!bi!ised ?Cl2 cells . 
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, After mechanical permeabilisation, cells are exposed to an in vitro reaction with ATP (ATP, creatine kinase 
. and creatine phosphate) for 15 minutes at 37°C. This allows the formation of small vesicles, which leak out of 
• the cell rather than fusing with their target organelles. This enables us to select for a larger population of 
.small vesicles than would be obtained in the absence of an in vitro reaction with ATP. 
Clathrin-coated vesicles can fuse with early endosomes but not with late endosomes. 
This specificity is due to the presence of SNAP proteins, target SNAP receptors 
(t-SNARE) and NSF on the surface of some intracellular compartments. The vesicle 
has on its surface vesicle SNAP receptors (v-SNAREs) which bind the SNAP proteins 
on the surface of the compartment. NSF then stimulates fusion of the vesicle to the 
compartment (Rothman and Warren, 1994; Diaz et al., 1989). After fusion with the 
early endosomes, proteins that are destined for the late endosome are separated from 
those that are recycled to the plasma membrane. Those proteins destined for the late 
endosome are packaged into small spherical vesicles called multivesicular bodies 
(MVBs) or endosomal carrier vesicles (ECVs) (reviewed in Gruenberg and Maxfield, 
1995). Sorting and recycling of proteins occurs in regions of the early endosome that 
differ in their structure (Gruenberg and Maxfield, 1995). 
Proteins that have been implicated in membrane transport are small GTPases of the 
Rab family. Early and late endosomes each contain a unique set of Rab proteins. Rab 
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5 mediates early endosome fusion (Gorvel et al., 1991). Rab 4 has been implicated in 
the recycling process from early endosomes back to the plasma membrane (Van der 
Sluijs et al., 1992). Rab 9 is required for transport from the late endosome to the 
trans-golgi network (TGN) and lysosome biogenesis (Riederer et al. , 1994). The exact 
role of Rab proteins is unclear, but it is believed that GTP hydrolysis aids vesicle 
fusion. 
Evidence for the internalization of activated TrkA can be found in studies by Grimes et 
al., (1996) and Grimes et al. , (1997). Through confocal microscopy they determined 
that TrkA was localized in intracellular organelles near the plasma membrane. 
Clathrin co-localized with TrkA indicating that the intracellular organelles were 
clathrin-coated vesicles from endocytosis. They found NGF present in both large and 
small vesicles along with activated TrkA. This was good evidence signaling 
endosomes containing activated TrkA could retrogradely transport the NGF from the 
neurite tip to the cell body. 
Once a vesicle containing NGF-bound TrkA and several intracellular proteins also 
bound to TrkA, such as Ras and Raf (discussed in section 1.6.1) is generated then the 
vesicle can be transported to the nucleus, where target proteins such as MEK and ERK 
are located, to stimulate signal transduction. 
1.6: Signal Transduction 
1.6.1: The MAPK/ERK pathway 
The signaling pathway leading to the activation of MAPK, or ERK, is the 
best-characterized pathway and is summarized above (Figure 4). Ras binds and 
activates Raf. Raf then activates MAPK or ERK kinase (MEK), which is responsible 
for the activation of ERK. Activation of ERK by NGF has been seen in previous 
studies (Loeb et al., 1992, Hempstead et al., 1992). The ERK pathway has been shown 
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to be important for neuronal differentiation in PC 12 cells (Pang et al., 1995). When 
the activity of MEK was inhibited the NGF-dependent formation of neurites was 
consequently inhibited suggesting the ERK pathway is responsible for mediating 
NGF-stimulated neurite extension. ERK activates a number of essential proteins within 
the cell in response to NGF signaling and so the pathways that stimulate ERK have 
been closely studied. 
Plasma membrane 
Figure 4 
ERK Pathway 
Ras activation of the ERK pathway 
The protein Ras was believed to have played a pivotal role in the signal transduction of 
many cell types (Barbacid, 1987). Activated Ras (Ras bound to GTP) was able to 
induce the differentiation of PC12 cells to sympathetic neuron-like cells (Bar-Sagi and 
Feramisco, 1985; Noda et al. , 1985). Ras has some GTPase activity so over time, the 
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complex becomes Ras bound to GDP, the inactive form of Ras. The substitution of 
GDP for GTP is catalyzed by a guanidine nucleotide exchange factor that has sequence 
homology to the Drosophila protein, son of sevenless (mSOS). Ras GTPase activating 
protein (Ras-GAP) is responsible for stimulating the hydrolysis of GTP to GDP thus 
deactivating Ras. Ras-GAP has been shown to be a substrate of Trk.A by Cantley et 
al. , (1991 ) and it accumulates in PC12 cells upon NGF stimulation (Qui and Green, 
1991 ; Muroya et al. , 1992; Nakafu et al. , 1992). This demonstrates the complexity of 
NGF signalling since these results indicate NGF binding to Trk.A activates Ras-GAP. 
Nakafu et al. , (1992) demonstrated that Ras-GTP accumulated in cells and that this 
accumulation could be inhibited by the addition of a tyrosine kinase inhibitor, so Ras 
must have some role in NGF signaling. 
Once Ras had been shown to participate in NGF signaling, Thomas et al. ( 1992) 
determined its role. They expressed a dominant inhibitory Ras mutant in PC12 cells. 
After exposure to NGF, cells expressing the mutant Ras were deficient in the activation 
of ERK-1 and 2. Expression of a constitutively active form of Ras in PC1 2 cells was 
sufficient to activate ERK-1 and 2. They looked at other possible roles for Ras. Ras 
played no part in activating the kinase activity of Trk.A, nor did Ras affect the tyrosine 
phosphorylation of PLCy-1 . This report separated distinct signaling pathways 
activated in response to NGF. These are a Ras-dependent pathway (ERK activation), 
and a Ras-independent pathway (PLCy-1 activation, SNT activation). 
The next step was identifying the mechanism by which Ras is activated. Ras is active 
when it is complexed to GTP and inactive when it is complexed to GDP, therefore the 
activation of Ras must require the activity of the nucleotide exchange factor (mSOS). 
In C. elegans a small protein, Sem-5, is believed to be responsible for the formation of 
a protein complex that results in the activation of Ras (Clark et al. , 1992; Pawson, 
1992). A mammalian homologue, Grb2, has been cloned in screens for SH2 
containing proteins (Matuoka et al. , 1992). Grb2 contains two SH3 domains in 
addition to the SH2 domain. 
The protein SHC binds the intracellular domain of Trk.A (Rozakis-Adcock et al., 
1992). Grb2 has been shown to stimulate the formation of a multiprotein complex. 
Once SHC binds to the intracellular domain of Trk.A it is phosphorylated on specific 
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tyrosine residues. Grb2 binds SHC through its SH2 domain. Egan et al. (1993) 
showed that the Ras guanidine nucleotide exchange protein binds the SH3 domain of 
Grb2 through its proline rich domain, localizing mSOS to the plasma membrane for 
guanidine nucleotide exchange on Ras. 
Ras binds and activates Raf-I 
The function of Ras in the signaling pathway was clarified once it was discovered Ras 
is complexed with the serine/threonine kinase Raf-1 (A vruch et al., 1994; Vojitek et 
al. , 1993). It is thought Ras localizes Raf-1 to the plasma membrane. Raf-1 activation 
is dependent upon Ras' C-terminal farnesylation (Lerner et al. , 1995; Okada et al. , 
1996). Inhibition of Ras farnesylation leads to the formation of Ras-Raf complexes in 
the cytosol (Lerner et al. , 1995) indicating the addition of long chain fatty acids to the 
C-terminus of Ras is required for Ras localization to the plasma membrane 
consequently localizing Raf to the plasma membrane. Raf-1 activation in the absence 
of Ras can be achieved if Raf-1 is targeted to the plasma membrane usmg a 
membrane-targeting signal (Leevers et al. , 1994). 
The site of Ras binding on Raf was subsequently identified and termed the Ras binding 
domain (RBD). It was shown to be contained within residues 51-131 (Vojitek et al. , 
1993; Nassar et al. , 1995; Gorman et al. , 1996; Herrmann et al. 1995; Hermann et al., 
1996). Ras binds Raf through this domain with high affinity (Herrmann et al. , 1995; 
Herrmann et al. 1996). 
A second Ras binding domain containing the cysteine rich domain (CRD) was found to 
also contain a zinc finger (Mott et al., 1996). This cysteine rich domain spans residues 
139-184. It is unclear whether Ras binding to CRD is GTP-dependent or whether Ras 
needs to be modified with a long chain fatty acid to bind. Roy et al. (1997) showed the 
RBD was sufficient for the recruitment of Raf-1 to the plasma membrane and the Zinc 
finger played no part in this recruitment. They also demonstrated that the presence of 
the Zinc finger was required for membrane localization of Raf-1. By using a 
constitutively active form of Raf-1, they found Raf-1 activity was only fully achieved 
when Ras was co-expressed even though Raf-1 was constitutively associated with the 
plasma membrane. This sensitivity to Ras was abolished by a mutation in the Zinc 
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finger region of Raf-1, suggesting two roles for Ras in Raf-1 activation; binding of Ras 
to the RBD for localization to the plasma membrane and Ras binding to the CRD for 
Raf-1 activation in a manner that requires the Zinc finger. 
The co-association of Ras and Rap-lA, a protein with an identical effector domain for 
Raf-1 binding, interferes with the Ras-dependent activation of Raf-1 (Hu et al., 1997) 
because of its ability to bind Raf-1. Although Rap-1 A has high sequence homology 
with Ras as well as an identical effector domain it was not able to activate Raf-1. 
Critical residues in the Ras effector domain were replaced with residues in the same 
position on Rap-lA. This mutant form of Ras (Ha-Ras) was found to bind Raf-1 with 
high affinity, as was Rap-lA, through their RBD and CRD respectively. Association of 
Ha-Ras and Rap-lA with Raf-1 prevented its activation. This proved Ras binds to 
Raf-1 on two domains. One domain for localization to the plasma membrane (RBD) 
and a second Ras interaction site that is required for Raf-1 activation. 
The activation of Raf-1 is more complicated than the association of Ras with Raf-1. 
The physiological substrate of Raf-1 , MEK, is also believed to bind Raf-1 (Van Aelst 
et al., 1993; Catling et al., 1995) as are members of the protein family 14-3-3 
(Morrison, 1994). The 14-3-3 interaction was particularly confusing because it has 
been shown to be constitutively associated with Raf-1 regardless of the activation state 
of Raf-1, and has also been shown to suppress Raf-1 activity (Irie et al., 1994; Fantl et 
al., 1994; Freed et al. , 1994; Michaud et al., 1995). 14-3-3 is a specific phosphoserine 
binding protein and Raf-1 has two such phosphorylation sites, S-259 and S-621. 
Mutations in the CRD of Raf-1 abolish 14-3-3 binding suggesting that 14-3-3 interacts 
with Raf-1 in the CRD (Michaud et al., 1995). Other proteins that have been shown to 
bind Raf-1 include the heat shock proteins hsp90 and hsp50 (Wartmann et al., 1994; 
Stepanova et al., 1996). Kinase suppressor of Ras (KSR) also binds to Raf-1 at the 
plasma membrane in a Ras-dependent manner (Therrien et al., 1996). 
A model of Raf-1 activation was proposed (Morrison and Cutler, 1997) (Figure 5). 
There are three conserved regions of Raf-1. Conserved region 1 (CRl) contains the 
RBD and CRD. CR2 (residues 254-269) is rich in threonine and serine residues. CR3 
is the kinase domain of Raf-1. Ras binds to the RBD of Raf-1 causing plasma 
membrane localization. This allows the binding of Ras to the second binding site 
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(CRD). This second binding cannot occur without Ras binding first to the RBD 
(Drugan et al., 1996). The CRD may also be responsible for bringing together other 
protein members of the protein complex (Michaud et al., 1995). The presence of 
14-3-3 may maintain Raf-1 in a conformation that prevents Ras binding to CRD. This 
would reduce the chance of cytosolic active Ras-Raf-I complexes, which could harm 
the cell. This was proposed because the mutations that allow Ras to bind CRD in the 
absence of RBD binding occur in the residues responsible for 14-3-3 binding (Michaud 
et al., 1995). 14-3-3 may play a secondary role in stabilizing the active conformation 
of Raf-1 . This interaction would prevent the inactivation of Raf-I by phosphatase 
treatment since it could interact with phosphoserine 621 (Muslin et al., l 996; Dent et 
al., 1995). 14-3-3 molecules are able to dimerise to form heterodimers. This would 
suggest a role for 14-3-3 as a protein that is responsible for the formation of higher 
order protein complexes (Xiao et al., 1995; Liu et al., 1995). Hsp50 and hsp90 act as 
stabilizing proteins whereas the binding of MEK is believed to place it in close 
proximity to Raf-I for activation. The possibility of phosphorylation as a mediator of 
Raf-I activity has been noted (Morrison et al., 1993). In this model it has been 
suggested that phosphorylation of serine, and possibly other residues would then 
provide specific binding sites for regulatory proteins such as 14-3-3 binding 
phosphoserine residues . The regulation of Raf-1 is a complex mechanism and is an 
important step in the survival of the cell in response to NGF. 
The importance of Raf- I for cell signaling was shown in a study by Lenormand et al. 
(1996). They showed Raf-1 was responsible for the regulation of S6 kinase activity. 
They expressed an oestradiol-regulated form of Raf-I in Chinese hamster lung 
fibroblast cells and blocked the activation of ERK with phosphatase treatment. In 
these conditions, the activation of Raf-1 was able to mediate S6 kinase activation. In 
addition to this, Raf- I was found to activate MEK, the kinase responsible for the 
activation of ERK (Catling et al., 1995). 
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14-3-3 is believed to play an essential role in Raf activation. It is bound to Raf in a way that prevents the 
cysteine rich domain from binding Ras-GTP. Once Raf binds Ras through the Ras binding domain, 
14-3-3 is displaced and binds to the cysteine rich-3 region stabilizing the Ras-Raf complex. Other 
proteins are believed to participate in Raf activation. 
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The importance of MEK in the ERK pathway 
As mentioned previously, MEK is believed to bind Raf-1 and is consequently activated 
by Raf-1 . MEK is a tyrosine/threonine kinase that is responsible for activating ERK 
(Kosak.a et al. , 1992; Crews et al. 1992; Robbins et al., 1993). ERK is active once its 
threonine and tyrosine residues have been phosphorylated. MEK is unable to 
recogmze denatured ERK (Seger et al. , 1992). This suggests that the three 
dimensional structure of ERK is important for MEK mediated activation. Several 
isoforms of MEK and ERK exist so it was hypothesized that there must be some 
structural recognition to ensure that the correct MAPK family member is activated by 
the appropriate MEK. Robinson et al . (1996) produced several ERK mutants and their 
activation by the corresponding MEKs was studied. Mutations were introduced in the 
phosphorylation loop of ERK, either at the phosphorylation sites within the loop, or at 
residues between these sites. Mutations were also introduced to shorten the loop. 
They found that the length of the loop does not affect MEK specificity and that the 
only major determinant for specificity was the kinase backbone. 
It has also been proposed ERK can bind MEK on a docking site contained at the 
N-terminus of MEK (Bardwell and Thomer, 1996). Binding of ERK to MEK at this 
site would provide another level of specificity. The authors also suggest that the 
MEK-ERK complex would be too tight to allow the transfer of phosphate from ATP to 
ERK. Therefore, the activation of ERK would need to be a two step process. The first 
step would be the binding of the correct ERK and MEK determined by the kinase 
domain and N-terminal specificity, and the second step would require a dissociation of 
the two proteins, which would remain in close proximity for ATP to bind and 
phosphotransfer to occur. 
MEK activates ERK in the cytoplasm (Lenormand et al. , 1993; Zheng et al., 1994b) so 
the question asked was; how does MEK become localized to the cytoplasm? This 
question was looked at by Fukuda et al. , (1996). Using deletion mutants , they 
discovered that MEK contains a nuclear export signal within its N-terminal domain. 
The model proposed for the MEK-dependent activation of ERK was that MEK is 
translocated to the cytoplasm through its nuclear export signal where it binds ERK and 
activates it. 
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It is possible that other proteins have a role in regulating the activation of MEK. It is 
widely accepted that Raf is responsible for the activation of MEK. Zheng et al. (1994) 
reported that they immunodepleted Raf from PC 12 cells and observed an 
NGF-dependent activation of MEK. One group has identified a protein kinase that 
plays a role in MEK activation. Pang et al. (1995b) have characterized this novel 
kinase in PC12 cells and found that its activity was stimulated three-fold in response to 
NGF. It is approximately 50 KDa in size with an isoelectric point of 7.3. The kinase 
activity was specific for ATP and requires Mg2+ as a cofactor. The enzyme was not 
activated when a dominant inhibitory mutant form of Ras was expressed in PC12 cells 
suggesting that this kinase is downstream of Ras. Site directed mutation of the 
residues on MEK that are required for activation by Raf-1 showed a decreased, but no 
inhibition, of MEK phosphorylation suggesting this kinase may share some common 
residue targets for phosphorylation of MEK as well as targeting novel residues. 
ERK 
The importance of ERK activation can be seen by the different responses that occur as 
a result of ERK' s duration of activation. After NGF stimulation the activity of ERK 
remains active for hours, yet EGF stimulation results in a short lived ERK activity, one 
that can be measured in minutes (Heasley and Johnson, 1992; Traverse et al., 1992; 
Nguyen et al., 1993). The is that NGF stimulates a differential response while 
EGF stimulates a proliferative one. The only other difference in ERK activation 
between the two responses is that ERK activation is achieved through a complex 
formation of SHC, Grb2 and mSOS in response to NGF. However in response to EGF, 
ERK is activated through the formation of a Grb2, mSOS complex (Obermeier et al., 
1994; Stephens et al., 1994). The EGF receptor is more rapidly down regulated than 
TrkA through internalization and phosphorylation (Countaway et al., 1992) suggesting 
it is the number of active cell surface receptors that determines the time period that 
ERK is active. Why the difference in activation times? Transient activation leads to a 
different cellular response than a sustained activation. During sustained ERK 
activation, ERK. is translocated to the nucleus (Chen et al., 1992; Traverse et al., 1992; 
Nguyen et al., 1993). The nuclear translocation of ERK would mean that certain 
transcription factors are targets for ERK activity. A sustained ERK activity could lead 
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to critical changes in gene expression. This could stimulate the expression of those 
genes that are required for cell survival. 
Various isoforms of ERK exist. They are all serine/threonine kinases and require 
phosphorylation of their tyrosine and threonine residues for maximal activation. The 
localization of ERK was expected to be in the cytosol because ERK is a target for the 
EGF receptor (Northwood et al., 1991). Alvarez et al., (1991) showed that ERK was 
also localized to the nucleus. Thus, the translocation of ERK to the nucleus provides a 
physical link between NGF binding to its receptor and signaling events within the 
nucleus. 
ERK targets includes kinases and phosphatases. Raf and MEK are phosphorylated by 
ERK in vitro (Anderson et al., 1991; Lee et al., 1992; Matsuda et al., 1993) suggesting 
ERK is capable of self-regulation. ERK has also been shown to phosphorylate S6 
kinase. Two different types of S6 kinase are phosphorylated in response to NGF and 
EGF treatment (Mutoh et al. 1988). This showed that the prolonged activation of ERK 
seen with NGF stimulation activated a different S6 kinase than EGF signaling. This 
could account for the fact that NGF results in differentiation while EGF stimulates 
proliferation. 
Other factors could be involved in ERK activation 
Other proteins have been shown to regulate the activation of the ERK signaling 
cascade. Cells treated with 12-0-tetradecanoylphorbol-13-acetate (TPA) show 
activation of ERK (Ray et al., 1987; Hoshi et al., 1988; Rossomando et al., 1989) 
suggesting an involvement of PKC in this pathway. A direct demonstration of this 
effect was shown by Ueda et al. , (1996) when they found that TPA mediated activation 
of ERK was not blocked when a dominant negative form of Ras was expressed. They 
demonstrated that PKC8 could activate ERK but Raf was required. This event 
appeared to be Ras-independent but TPA modulates effectors of Ras so any result for 
Ras could not be taken into account. Evidence has also been provided for the 
requirement of other signaling cascades in ERK activation (Grammer and Blenis, 
1997). These results demonstrate that the activation of ERK is not just a clear linear 
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pathway. Its activation could be a complex system of cross talk between different 
pathways activated by NGF. 
To summarize the activation of ERK through NGF stimulation: the protein She binds 
to a phosphotyrosine residue on the intracellular domain of TrkA. This phosphorylates 
tyrosine residues on She providing a binding site for Grb2. Grb2 localizes mSOS to 
the plasma membrane. mSOS exchanges GDP for GTP on Ras thus activating it. 
Plasma membrane-bound Ras binds the RBD on Raf-1. This achieves two things; it 
localizes Raf-1 to the plasma membrane and it displaces 14-3-3, which is bound to 
phosphoserine residues on Raf-1. This displacement exposes a CRD on Raf-1 to 
which Ras is able to bind resulting in Raf-1 activation. Raf-1 then activates MEK, 
which has been localized to the cytoplasm through its nuclear export signal. MEK in 
turn phosphorylates, and activates, ERK. ERK then continues the signal by 
phosphorylating other signaling proteins and transcription factors. These targets of 
ERK trigger events that are responsible for the survival of the cell. 
1.6.2: The PBK pathway 
As mentioned in section 1.3.3, other intracellular proteins are recruited to the 
intracellular domain of TrkA in response to NGF binding. These proteins trigger other 
signaling cascades that also have importance in cellular survival. The binding of 
phosphotidylinositol-3 kinase (PI-3K) to the intracellular domain triggers one such 
pathway. Ohmichi et al. (1992) showed tyrosine phosphorylation of PBK in 
anti-phosphotyrosine immunoprecipitates but not in anti-TrkA immunoprecipitates. 
This suggested PBK is tyrosine phosphorylated in response to NGF but it is not 
associated directly with TrkA. They proposed that there is an SH2 containing protein 
that links PI-3K to TrkA intracellular domain. In contrast some studies have provided 
evidence for PI-3K binding to the TrkA intracellular domain through its p85 regulatory 
subunit (Soltoff et al., 1992; Obermeier et al., 1993a; Obermeier et al., 1993b). It 
remains unclear as to whether PI-3K directly or indirectly interacts with the 
intracellular domain of TrkA. 
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The action of PI-3K is in the formation of phosphoinositides, which act as secondary 
messenger molecules. PI-3K can phosphorylate various forms of phosphoinositides to 
form phosphatidylinositol-3-phosphate (Ptdins-3-P), phosphatidylinositol-3,4-
bisphosphate (Ptdins-3,4-P2) and phosphatidylinositol-3,4,5-trisphosphate (Ptdins-
3,4,5-P3). The formation of Ptdins-3-P can occur without NGF stimulation but the 
formation of Ptdins-3,4,5-P3 occurs only in response to NGF. The formation of Ptdins-
3,4-P2 and Ptdins-3,4,5-P3 is regulated through a complex series of kinases and 
phosphatases. This is important because certain SH2 and Pleckstrin Homology (PH) 
domains can interact with Ptdins-3,4,5-P3 (Carpenter and Cantley, 1996). In addition, 
the serine/threonine protein kinase B (Akt) is activated by Ptdins-3,4-P2 (Franke et al., 
1997; Klippel et al. , 1997). 
P/3K activates Akt 
The activity of Akt is regulated by growth factors that regulate the activity of PI-3K 
(Franke et al. , 1995; Burgering and Coffer, 1995). These studies found receptor 
mutants deficient in activating PI-3K failed to activate Akt and the expression of 
dominant inhibitory alleles of PI-3K also prevented Akt activation. Finally, they found 
constitutively active PI-3K increased Akt activity independent of growth factors and 
the PI-3K inhibitor wortmannin inhibited Akt activity. Franke et al. (1995) also 
showed Akt activation was partially dependent on Ras . This had been noted by 
Klippel et al. ( 1996) who demonstrated that activated mutants of Ras might stimulate 
Akt by activating PI-3K. However, Akt is not involved in the activation of ERK 
(Franke et al. , 1995). Another pathway, independent of PI-3K, that plays a role in Akt 
activation could involve p38/HOG (Alessi et al., 1996). 
Akt molecules have the ability to form homodimers and interact with other 
intracellular proteins through its PH domain (Datta et al., 1995). Treatment of Akt 
with serine and threonine phosphatases has shown the importance of phosphorylation 
on these residues for Akt activity. The critical phosphorylation sites have been shown 
to be threonine 308 and serine 473 (Alessi et al., 1996). p38/HOG activates 
MAPKAP2 (MAPK activating protein also known as MEK) under conditions of 
cellular stress when PI-3K is not activated (Alessi et al., 1996). Therefore, it may be 
possible that this pathway is responsible for the phosphorylation on S-473 in vivo. 
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It is still unclear how PI-3K activates Akt. Klippel et al., (1997) used vesicles 
containing Ptdins-3-P, Ptdins-3,4-P2 or Ptdins-3 ,4,5-P3 to observe whether the products 
of PI-3K are able to activate Akt in vivo. They found that only those vesicles that 
contained Ptdins-3,4-P2 were able to activate Akt. This activation was dependent on an 
intact PH domain, which has the ability to bind phosphoinositides. This result was also 
shown by Franke et al. (1997) who found that binding of Ptdins-3,4-P2 stimulated the 
dimerization of Akt. Stephens et al. (1998) showed binding of Ptdins-3,4,5-P3 occurs 
on the PH domain of Akt. This caused translocation of Akt to the plasma membrane 
and allowed upstream kinases to phosphorylate threonine 308. Four isoforms of this 
kinase were isolated from sheep brain cytosol. From these it was discovered the kinase 
contains an N-terminal catalytic domain and a C-terminal PH domain. Expression of 
this kinase augmented receptor activation of Akt. In another study, chromatographic 
separation of cytosol revealed a kinase activity that was able to phosphorylate Akt 
(Stokoe et al., 1998). This phosphorylation, exclusively on threonine 308, could only 
occur in the presence of Ptdins-3,4,5-P3. 
Several downstream targets of Akt have recently been identified. Targets include 
glycogen synthetase kinase-3 (GSK3) which is not involved in cellular survival. This 
suggests that Akt has other roles within the cell besides cellular survival. p70 S6 
kinase is downstream of Akt (Burgering and Coffer, 1995). Most importantly Akt has 
been implicated in having an effect on members of the Bcl-2 family. 
1.6.3: The Bcl-2 family and Caspases. 
The cell machinery that has been shown to be responsible for apoptosis involves 
caspases and Bcl-2 family members. Caspases are specific proteases that can be 
defined into two major groups; those responsible for the terminal phase of apoptosis 
(executors), and those that activate the executors (initiators). The Bcl-2 family 
members are groups of proteins that can either be pro-apoptotic (Bax, Bad, and Bak) or 
anti-apoptotic (Bcl-2, Bel-XL, Al, and Bag-1). In general the Bcl-2 family members 
regulate the activation of caspases through interactions with other intracellular proteins 
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and/or through the control of ion fluxes across intracellular membranes. Most of these 
proteins have been studied for their roles in apoptosis by looking at the simpler model 
of apoptosis in C. elegans. 
The Bcl-2 family 
The pathways involving the Bcl-2 family members and caspases are responsible for 
regulating the final event of apoptosis. They in tum are regulated by those signaling 
pathways we have discussed so far - those activated by proteins that directly associate 
with the intracellular domain of TrkA. One such link is the phosphorylation of Bad by 
Akt (Datta et al., 1997; del Peso et al., 1997). Scheid and Duronio (1998) also 
demonstrated this result as well as providing evidence for the phosphorylation of Bad 
through a PI-3K independent pathway, probably through MEK. 
Phosphorylation of Bad, a protein that normally dimerises with Bcl-2 and Bel-XL 
through interaction of the BH3 domain of Bad (Zha et al., 1997; Ottilie et al., 1997; 
Kelekar et al. , 1997), results in inhibition of apoptosis. Phosphorylation of Bad occurs 
on two serine residues and this allows Bad to bind a member of the 14-3-3 family of 
proteins (Zha et al. , 1996). This association frees Bcl-Xdor binding to Bax preventing 
the pro-apoptotic effect of Bax. Mutation of these phosphorylation sites on Bad result 
in loss of cell survival by cytokines (Zha et al., 1996). 
The roles of the Bcl-2 family members remain unclear. Bcl-2 has been overexpressed 
in many cell types and has been shown to inhibit the apoptotic response induced by a 
variety of factors (Reed, 1994). Endogenous and exogenous Bcl-2 are anchored via 
their hydrophobic C-terminal domains to the outer membranes of mitochondria, nuclei, 
and the endoplasmic reticulum with most of the protein being exposed to the cytosol 
(Nguyen et al., 1993; Chen-Levy and Cleary, 1990; Hockenberry et al., 1990). 
Membrane localization of Bcl-2 is required for maximal activation (Hockenberry et al., 
1993; Tanaka et al., 1993). Bcl-2, which has been implicated as an anti-oxidant 
(Hockenberry et al., 1993; Kane et al., 1993), preserves the potential of mitochondrial 
membranes (Hennet et al., 1993), and blocks the release of calcium from the 
intracellular stores (Baffy et al., 1993). Its most characterized function is as an 
inhibitor of caspases. Bcl-2 is able to bind other members of the family that have a 
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pro-apoptotic role, such as Bax. Otter et al., (1998) showed the degree of protection 
from apoptosis does not correlate to the number of Bel-2-Bax heterodimers. It was 
regulated by the amount of Bcl-2 that is free of Bax. Their study determined the 
Bel-2-Bax heterodimer is a pro-apoptotic complex and Bel-2 acts as an enzyme, either 
as a homodimer or as multimer. 
Bel-XL has been shown to have structural homology to a bacterial pore forming protein 
(Muchmore et al., 1996) which has been shown to form ion channels in synthetic 
biolipid bilayers (Minn et al. , 1997). By analogy, it is possible Bcl-2 also has the 
ability to form ion channels. These ion channels could regulate homeostasis of 
organelles during the apoptotic process. 
During apoptosis, the mitochondrial matrix swells and hyper-polarization of the 
mitochondrial inner membrane occurs resulting in the loss of electron transport and 
oxidative phosphorylation. Consequently, disruption of the outer membrane occurs 
resulting in the release of cytochrome c. These events can be prevented by the 
expression of Bel-XL (Vander Heiden et al., 1997). This is good evidence for the 
suggestion Bel-XL forms an ion channel in the mitochondrial membrane. 
The Bel-XL ion channel was studied by Lam et al. (1998). They expressed full length 
Bel-XL in a lipid bilayer reconstitution system and found Bel-XL formed a 
sodium-conducting channel, which was inhibited by luminal calcium. 
The release of cytochrome c from mitochondria during apoptosis is an essential event 
because it has been implicated in regulating the activation of caspases. In particular it 
is known to activate caspase-3 (Liu et al., 1996). The release of cytochrome c has been 
proposed to occur by two possible methods. Firstly, the mitochondrial disruption of 
the outer membrane could lead to the formation of pores through which cytochrome c 
could leak. This has been suggested because during apoptosis the permeability 
transition of mitochondria increases (Petit et al. , 1996). The other possibility is that 
Bax and Bad form specific channels. This is supported by the fact Bax induces 
cytochrome c release from mitochondria when expressed in yeast (Manon et al., 1997). 
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Caspase Activation 
The next area of study was the activation of caspases by cytochrome c. Most of the 
knowledge about caspase action has been gained by studying the nematode C. elegans. 
In C. elegans three genes have been identified that control apoptosis. Two genes, 
ced-3 and ced-4, are required for apoptosis to occur (Yuan and Horvitz, 1990). A third 
gene, ced-9, negatively regulates the functions of ced-3 and ced-4. It is proposed to lie 
upstream of the other two genes (Hengartner et al., 1992). This apoptotic process is 
conserved in mammals but with more complexity. Bcl-2 is the homologue of ced-9 
(Hengartner and Horvitz, 1994), a series of cysteine proteases are homologues of ced-3 
(Yuan et al. , 1993; Femandes-Alnemeri et al. , 1994; Alnemeri et al. , 1996) and Apaf-1 
(apoptotic protease activating factor) is homologous to ced-4 (Zou et al. , 1997). 
Apaf-1 has the ability to activate caspase-3 . Cytochrome c had also been previously 
found to play a role in caspase-3 activation (Liu et al. , 1996). This activation by 
cytochrome c could be inhibited by the expression of Bcl-2 (Yang et al. , 1997). 
Apaf- 1 has a CED-4 like domain that is flanked on one side by a CED-3 like domain 
(this also has sequence homology to caspases-2, -9, -11 ) and caspase recruitment 
domains (CARD) (Irmler et al. 1997). On the other side there are 12 WD repeats (Zou 
et al. , 1997). 
In C. elegans CED-3 , CED-4 and CED-9 are in a complex with each other (Chinnaiyan 
et al. , 1997; Wu et al., 1997; Spector et al. , 1997). In mammals, Apaf-1 can bind 
caspase-9 (previously known as Apaf-3, Li et al. , 1997) in the presence of 
cytochrome c and ATP. This protein complex is able to activate caspase-3 (Liu et al., 
1996; Vaux 1997). This interaction is mediated through the CARD domains. Pan et 
al. (1998) showed Bel-XL was bound to Apaf-1 and caspase-9 in a ternary complex, 
which inhibits the apoptotic response. They also found expression of dominant 
negative caspase-9 inhibited apoptosis suggesting caspase-9 is a downstream target of 
Apaf-1 and its activation is critical for apoptosis. 
A model is presented where cytochrome c binds to the WD repeats of Apaf-1 inducing 
a conformational change. This change in conformation allows Apaf-1 to bind 
caspase-9 in an ATP dependent manner (Reed, 1997). Caspase-9 then cleaves 
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caspase-3 leading to its activation. Caspase-3 activates further downstream caspases 
inducing apoptosis. Bcl-2/Bcl-XL is able to inhibit this process by binding the 
Apaf-1-caspase-9 ternary complex. This prevents the activation of caspase-3, 
protecting the cell from apoptosis. 
Other methods of caspase-3 activation occur within the cell. Ceramide has been linked 
to caspase-3 activation (Yoshimura et al. 1998) suggesting a method whereby the p75 
receptor, which has been linked to ceramide formation (Dobrowsky et al., 1994), can 
induce apoptosis via caspase-3 activation. Calcium has been found to increase the 
activity of caspase-3 (Juin et al. , 1998). This was consistent with their discovery that 
the addition of calcium to a cell free system triggered nuclear apoptosis (DNA 
fragmentation) . 
Apoptosis needs to be tightly regulated to ensure the cell functions in an appropriate 
manner. This requires a certain amount of cross talk between different pathways as has 
been discussed in previous sections. NGF-activated TrkA activates several signaling 
pathways at the plasma membrane. Other signaling pathways are activated by 
intracellular organelles containing active TrkA. These signals activate downstream 
pathways responsible for the physical effects of apoptosis such as mitochondrial 
swelling and DNA fragmentation. 
Many intracellular pathways activate or inhibit apoptosis. To be able to manipulate 
apoptosis we need to understand its control at the molecular level. The purpose of the 
projects described in this thesis is to examine the initial molecular interactions that 
occur upon NGF binding. That is, the recruitment of several intracellular proteins to 
the intracellular domain of activated TrkA. Several of these proteins have already been 
identified (discussed in section 1.3.3). The intracellular domain of TrkA contains 
many tyrosine residues that are phosphorylated upon NGF binding. These residues 
could provide binding sites for additional intracellular proteins that have not yet been 
identified as Trk.A binding proteins. A set of such proteins had been seen previously 
(Dr. M. L. Grimes, unpublished results). My aim was to isolate and characterize these 
proteins. To achieve this I attempted to express and purify the intracellular domain of 
Trk.A in bacteria. The protein was found to be expressed in a tyrosine-phosphorylated 
form suggesting that it was constitutively active. This provides us with an opportunity 
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to identify proteins that are activated and those that bind to activated TrkA by adding 
the protein to cytosol from PC12 cells that have not been treated with NGF. This will 
further clarify the molecular regulation of apoptosis and bring us closer to being able to 
manipulate the decision to undergo apoptosis. 
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